OC 60.2 - Emicizumab Treatment is Efficacious and Well Tolerated Long Term in Persons with Haemophilia A (PwHA) with or without FVIII Inhibitors: Pooled Data from Four HAVEN Studies

  • Presentation
Oral Communication Session
2022 © International Society on Thrombosis and Haemostasis. Licensed with permission. All rights reserved.
Meeting: ISTH 2019 Congress
Presenter: M. Callaghan
Presentation Date: July 9, 2019
Abstract #: OC 60.2 / 358

Disclaimer

This content was selected by and is provided to you courtesy of Your Company.
2022 © International Society on Thrombosis and Haemostasis. Licensed with permission. All rights reserved.

ISTH played no role in the reproduction of the product and is not responsible for any errors, omissions, or other possible defects in this reproduction.

The views and opinions expressed in the presentations, talks, slides and discussions selected for this website, are those of the authors/presenters and do not necessarily reflect the view of the International Society on Thrombosis and Haemostasis (ISTH). The content of this website is a selection of content from the ISTH 2021 Congress, and it is intended for scientific educational/information purposes only; it is not intended for diagnostic purposes and/or to determine choice of treatment.

The program and the content of the presentations is owned by the ISTH and by the respective authors/presenters and may include discussions on off label data of products and therapies. The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.

It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine the best treatment for the patient. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. You are also encouraged to contact the manufacturer with questions about the features or limitations of any products. Any decisions you make based on the information provided is voluntary and should only be undertaken after an independent review of its accuracy, completeness, efficacy, and timeliness. Any decisions as to how you use this information is in your sole discretion and ISTH assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.  All content is provided “as is.” You acknowledge and agree that information and products provided may not be complete or accurate.  In no event shall ISTH be liable for any direct, indirect, consequential, incidental or indirect damages suffered in the course of using the information provided.

This site is for access and use by healthcare professionals only. If you are not a healthcare professional, you must not access the site. By accessing and visiting the site, you confirm that you are a healthcare professional, and that you agree with the disclaimer outlined above.

YOU AGREE NOT TO TAKE ACTION AGAINST, OR SEEK TO HOLD, OR HOLD LIABLE, ISTH FOR YOUR USE OF THE INFORMATION PROVIDED.

Site provided by Springer Healthcare Limited. Part of the Springer Nature Group.

Selected Presentation from the ISTH Congress (For Demo Purposes Only)

Emicizumab Treatment is Efficacious and Well Tolerated Long Term in Persons with Haemophilia A (PwHA) with or without FVIII Inhibitors: Pooled Data from Four HAVEN Studies

Content Available: Presentation Video

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
Please note, this is for demo purposes only. Your data will not be collected.
2022 © International Society on Thrombosis and Haemostasis. Licensed with permission. All rights reserved.